Cell And Gene Therapy Manufacturing

  1. Why Clinical Requirements Change: Dr. Peter Marks on Pre-IND Meeting Pathways 1/30/2024

    Learn how clinical requirements change after the FDA and a company agree on a pathway during a pre-IND meeting and how the company might recover as a result.

  2. Optimize Cell Isolation And Activation For Flexibility And Scalability 11/13/2023

    Learn about a first-of-its-kind platform technology that enables isolation and activation of T cells in one step using an active release mechanism for clinical trial or commercial manufacturing.

  3. DynaDrive Single-Use Bioreactors - One Reactor, Many Volumes 3/30/2026

    Single-use bioreactors with turndown ratios up to 20:1 enable facilities to operate across wide volume ranges within the same vessel, streamlining seed trains and reducing capital requirements for multi-product operations.

  4. DoE Methodology For Downstream Purification Of pDNA Of IEX Resins 6/16/2025

    Learn a systematic approach using Design of Experiment to optimize plasmid DNA purification. See how anion exchange resins are evaluated to enhance dynamic binding capacity and process efficiency.

  5. Knowledge Culture Basics — Gene Therapy Education Series: Lentiviral Vectors 6/9/2025

    In this session of our ongoing education series on lentiviral vectors, we delve further into principles of lentiviral transduction and challenges in suspension-based lentivirus production.

  6. Inside Bioprocessing: Continuous Perfusion 11/4/2025

    Learn about the essential elements of upstream workflows, media optimization strategies, and liquid handling logistics required to implement continuous perfusion successfully.

  7. Multi-Omics In Cell Culture Media Design 11/4/2025

    Discussing the evolution of medium design for cell culture bioprocessing, and the role that multi-omics and bioinformatics can play in improved medium development.

  8. Major Trends Impacting Allogeneic Cell Therapies For Oncology 5/6/2024

    We kicked off this Cell & Gene Live, Unlocking the Future of Allogeneic Cell Therapy for Oncology by discussing the major trends impacting allogeneic cell therapies for oncology.

  9. Considerations For Affinity Capture In An AAV Platform Downstream Process 6/2/2025

    This presentation explores the considerations when evaluating a platform affinity capture step for the purification of AAV vectors. Specificity, binding capacity, purity, yield, scalability and reusability are parameters that will be addressed.

  10. BPI Interviews Purification And Pharma Analytics Leader 6/9/2025

    Jean Luo, VP of Purification and Pharma Analytics, discusses innovations in bioprocessing, including the development of dPCR assays, lentiviral titer systems, chromatography resins, and supply chain.